<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39351091</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Novel multitarget analgesic candidate SZV-1287 demonstrates potential disease-modifying effects in the monoiodoacetate-induced osteoarthritis mouse model.</ArticleTitle><Pagination><StartPage>1377081</StartPage><MedlinePgn>1377081</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1377081</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1377081</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Monoiodoacetate (MIA)-induced osteoarthritis (OA) is the most commonly used rodent model for testing anti-OA drug candidates. Herein, we investigated the effects of our patented multitarget drug candidate SZV-1287 (3-(4,5-diphenyl-1,3-oxazol-2-yl) propanal oxime) that is currently under clinical development for neuropathic pain and characterized the mouse model through complex functional, <i>in vivo</i> imaging, and morphological techniques.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Knee OA was induced by intraarticular MIA injection (0.5 and 0.8 mg). Spontaneous pain was assessed based on weight distribution, referred pain by paw mechanonociception (esthesiometry), edema by caliper, neutrophil myeloperoxidase activity by luminescence, matrix metalloproteinase activity, vascular leakage and bone remodeling by fluorescence imaging, bone morphology by micro-CT, histopathological alterations by semiquantitative scoring, and glia activation by immunohistochemistry. Then, SZV-1287 (20 mg/kg/day) or its vehicle was injected intraperitoneally over a 21-day period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">MIA induced remarkably decreased thresholds of weight bearing and paw withdrawal, alterations in the tibial and femoral structures (reactive sclerosis, increased trabeculation, and cortical erosions), histopathological damage (disorganized cartilage structure, hypocellularity, decreased matrix staining and tidemark integrity, and increased synovial hyperplasia and osteophyte formation), and changes in the astrocyte and microglia density in the lumbar spinal cord. There were no major differences between the two MIA doses in most outcome measures. SZV-1287 inhibited MIA-induced weight bearing reduction, hyperalgesia, edema, myeloperoxidase activity, histopathological damage, and astrocyte and microglia density.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">SZV-1287 may have disease-modifying potential through analgesic, anti-inflammatory, and chondroprotective effects. The MIA mouse model is valuable for investigating OA-related mechanisms and testing compounds in mice at an optimal dose of 0.5 mg.</AbstractText><CopyrightInformation>Copyright © 2024 Horváth, Bölcskei, Szentes, Borbély, Tékus, Botz, Rusznák, Futácsi, Czéh, Mátyus and Helyes.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horváth</LastName><ForeName>Ádám István</ForeName><Initials>ÁI</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory for Drug Research and Development, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bölcskei</LastName><ForeName>Kata</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szentes</LastName><ForeName>Nikolett</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory for Drug Research and Development, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hungarian Research Network, HUN-REN-PTE Chronic Pain Research Group, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borbély</LastName><ForeName>Éva</ForeName><Initials>É</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory for Drug Research and Development, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tékus</LastName><ForeName>Valéria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hungarian Research Network, HUN-REN-PTE Chronic Pain Research Group, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Diagnostics, Faculty of Health Sciences, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botz</LastName><ForeName>Bálint</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusznák</LastName><ForeName>Kitti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Stress Research Group, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Futácsi</LastName><ForeName>Anett</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Stress Research Group, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czéh</LastName><ForeName>Boldizsár</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurobiology of Stress Research Group, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mátyus</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helyes</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory for Drug Research and Development, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hungarian Research Network, HUN-REN-PTE Chronic Pain Research Group, Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PharmInVivo Ltd., Pécs, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALGONIST Biotechnologies GmBH, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amine oxidase copper containing 3</Keyword><Keyword MajorTopicYN="N">analgesic drug development</Keyword><Keyword MajorTopicYN="N">osteoarthritic pain</Keyword><Keyword MajorTopicYN="N">semicarbazide-sensitive amine oxidase</Keyword><Keyword MajorTopicYN="N">transient receptor potential ankyrin 1</Keyword><Keyword MajorTopicYN="N">transient receptor potential vanilloid 1</Keyword><Keyword MajorTopicYN="N">vascular adhesion protein 1</Keyword></KeywordList><CoiStatement>Author ZH is a founder and shareholder of PharmInVivo Ltd. and ALGONIST Biotechnologies GmBH. This has no scientific or commercial conflict of interest with the current work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39351091</ArticleId><ArticleId IdType="pmc">PMC11439770</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1377081</ArticleId><ArticleId IdType="pii">1377081</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alcaraz M. J., Guillen M. I., Ferrandiz M. L. (2019). Emerging therapeutic agents in osteoarthritis. Biochem. Pharmacol. 165 (July), 4–16. 10.1016/j.bcp.2019.02.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.02.034</ArticleId><ArticleId IdType="pubmed">30826327</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso K., Izumi M., Sugimura N., Okanoue Y., Ushida T., Ikeuchi M. (2016). Nociceptive phenotype alterations of dorsal root ganglia neurons innervating the subchondral bone in osteoarthritic rat knee joints. Osteoarthr. Cartil. 24 (9), 1596–1603. 10.1016/j.joca.2016.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2016.04.009</ArticleId><ArticleId IdType="pubmed">27085969</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannuru R. R., Osani M. C., Vaysbrot E. E., Arden N. K., Bennell K., Bierma-Zeinstra S. M. A., et al. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. 27 (11), 1578–1589. 10.1016/j.joca.2019.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2019.06.011</ArticleId><ArticleId IdType="pubmed">31278997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bapat S., Hubbard D., Munjal A., Hunter M., Fulzele S. (2018). Pros and cons of mouse models for studying osteoarthritis. Clin. Transl. Med. 7 (1), 36. 10.1186/s40169-018-0215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-018-0215-4</ArticleId><ArticleId IdType="pmc">PMC6246759</ArticleId><ArticleId IdType="pubmed">30460596</ArticleId></ArticleIdList></Reference><Reference><Citation>Baragi V. M., Gabriel B., Bendele A. M., Biesinger R., Bluhm H., Boer J., et al. (2009). A New class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheumatism 60 (7), 2008–2018. 10.1002/art.24629</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24629</ArticleId><ArticleId IdType="pubmed">19565489</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaker C. L., Ashton D. M., Doran N., Little C. B., Clarke E. C. (2021). Sex- and injury-based differences in knee biomechanics in mouse models of post-traumatic osteoarthritis. J. Biomechanics 114 (January), 110152. 10.1016/j.jbiomech.2020.110152</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiomech.2020.110152</ArticleId><ArticleId IdType="pubmed">33285491</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom A. B., van Lent P. L., Libregts S., Holthuysen A. E., van der Kraan P. M., Rooijen N. van, et al. (2007). Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheumatism 56 (1), 147–157. 10.1002/art.22337</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22337</ArticleId><ArticleId IdType="pubmed">17195217</ArticleId></ArticleIdList></Reference><Reference><Citation>Botz B., Imreh A., Sándor K., Elekes K., Szolcsányi J., Reglődi D., et al. (2013). Role of pituitary adenylate-cyclase activating polypeptide and Tac1 gene derived tachykinins in sensory, motor and vascular functions under normal and neuropathic conditions. Peptides 43 (May), 105–112. 10.1016/j.peptides.2013.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2013.03.003</ArticleId><ArticleId IdType="pubmed">23499760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. (1992). A power primer. Psychol. Bull. 112 (1), 155–159. 10.1037//0033-2909.112.1.155</Citation><ArticleIdList><ArticleId IdType="doi">10.1037//0033-2909.112.1.155</ArticleId><ArticleId IdType="pubmed">19565683</ArticleId></ArticleIdList></Reference><Reference><Citation>Combe R., Bramwell S., Field M. J. (2004). The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? Neurosci. Lett. 370 (2–3), 236–240. 10.1016/j.neulet.2004.08.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.08.023</ArticleId><ArticleId IdType="pubmed">15488329</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallegri F., Bertolotto M., Ottonello L. (2005). A review of the emerging profile of the anti-inflammatory drug oxaprozin. Expert Opin. Pharmacother. 6 (5), 777–785. 10.1517/14656566.6.5.777</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.6.5.777</ArticleId><ArticleId IdType="pubmed">15934904</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng L. F., Ghirnikar R. S., Lee Y. L. (2000). Glial fibrillary acidic protein: GFAP-Thirty-One years (1969-2000). Neurochem. Res. 25 (9–10), 1439–1451. 10.1023/a:1007677003387</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1007677003387</ArticleId><ArticleId IdType="pubmed">11059815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernihough J., Gentry C., Malcangio M., Fox A., Rediske J., Pellas T., et al. (2004). Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 112 (1–2), 83–93. 10.1016/j.pain.2004.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2004.08.004</ArticleId><ArticleId IdType="pubmed">15494188</ArticleId></ArticleIdList></Reference><Reference><Citation>Filip A., Pinzano A., Bianchi A., Fève B., Jalkanen S., Gillet P., et al. (2016). Expression of the semicarbazide-sensitive amine oxidase in articular cartilage: its role in terminal differentiation of chondrocytes in rat and human. Osteoarthr. Cartil. 24 (7), 1223–1234. 10.1016/j.joca.2016.01.340</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2016.01.340</ArticleId><ArticleId IdType="pubmed">26851450</ArticleId></ArticleIdList></Reference><Reference><Citation>Global R., Incidence N. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet London, Engl. 392 (10159), 1789–1858. 10.1016/S0140-6736(18)32279-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32279-7</ArticleId><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey V. L., Dickenson A. H. (2009). Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57Bl/6 mice. Mol. Pain 5, 18. 10.1186/1744-8069-5-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1744-8069-5-18</ArticleId><ArticleId IdType="pmc">PMC2678995</ArticleId><ArticleId IdType="pubmed">19379487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawker G. A., Croxford R., Bierman A. S., Harvey P. J., Ravi B., Stanaitis I., et al. (2014). All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PloS One 9 (3), e91286. 10.1371/journal.pone.0091286</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091286</ArticleId><ArticleId IdType="pmc">PMC3946823</ArticleId><ArticleId IdType="pubmed">24608134</ArticleId></ArticleIdList></Reference><Reference><Citation>Horváth Á., Borbély É., Bölcskei K., Szentes N., Kiss T., Belák M., et al. (2018). Regulatory role of capsaicin-sensitive peptidergic sensory nerves in the proteoglycan-induced autoimmune arthritis model of the mouse. J. Neuroinflammation 15 (1), 335. 10.1186/s12974-018-1364-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1364-5</ArticleId><ArticleId IdType="pmc">PMC6276168</ArticleId><ArticleId IdType="pubmed">30509328</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A., Menghis A., Botz B., Borbely E., Kemeny A., Tekus V., et al. (2017). Analgesic and anti-inflammatory effects of the novel semicarbazide-sensitive amine-oxidase inhibitor SzV-1287 in chronic arthritis models of the mouse. Sci. Rep. 7 (January), 39863. 10.1038/srep39863</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39863</ArticleId><ArticleId IdType="pmc">PMC5220351</ArticleId><ArticleId IdType="pubmed">28067251</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A., Tekus V., Bencze N., Szentes N., Scheich B., Bolcskei K., et al. (2018). Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors. Pharmacol. Res. 131 (May), 231–243. 10.1016/j.phrs.2018.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.02.006</ArticleId><ArticleId IdType="pubmed">29438782</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath A., Tekus V., Boros M., Pozsgai G., Botz B., Borbely E., et al. (2016). Transient receptor potential ankyrin 1 (TRPA1) receptor is involved in chronic arthritis: in vivo study using TRPA1-deficient mice. Arthritis Res. and Ther. 18 (January), 6. 10.1186/s13075-015-0904-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0904-y</ArticleId><ArticleId IdType="pmc">PMC4718022</ArticleId><ArticleId IdType="pubmed">26746673</ArticleId></ArticleIdList></Reference><Reference><Citation>Horváth Á. I., Szentes N., Tékus V., Payrits M., Szőke É., Oláh E., et al. (2021). Proof-of-Concept for the analgesic effect and thermoregulatory safety of orally administered multi-target compound szv 1287 in mice: a novel drug candidate for neuropathic pain. Biomedicines 9 (7), 749. 10.3390/biomedicines9070749</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9070749</ArticleId><ArticleId IdType="pmc">PMC8301340</ArticleId><ArticleId IdType="pubmed">34209525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D., Imai Y., Ohsawa K., Nakajima K., Fukuuchi Y., Kohsaka S. (1998). Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 57 (1), 1–9. 10.1016/s0169-328x(98)00040-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0169-328x(98)00040-0</ArticleId><ArticleId IdType="pubmed">9630473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalbhen D. A. (1987). Chemical model of osteoarthritis--a pharmacological evaluation. J. Rheumatology 14, 130–131.</Citation><ArticleIdList><ArticleId IdType="pubmed">3625668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly S., Chapman R. J., Woodhams S., Sagar D. R., Turner J., Burston J. J., et al. (2015). Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain. Ann. Rheumatic Dis. 74 (1), 252–259. 10.1136/annrheumdis-2013-203413</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203413</ArticleId><ArticleId IdType="pmc">PMC4283626</ArticleId><ArticleId IdType="pubmed">24152419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly S., Dobson K. L., Harris J. (2013). Spinal nociceptive reflexes are sensitized in the monosodium iodoacetate model of osteoarthritis pain in the rat. Osteoarthr. Cartil. 21 (9), 1327–1335. 10.1016/j.joca.2013.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2013.07.002</ArticleId><ArticleId IdType="pubmed">23973147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuswanto W., Baker M. C. (2024) “Repurposing drugs for the treatment of osteoarthritis,” in Osteoarthritis and cartilage. W.B. Saunders Ltd. 10.1016/j.joca.2024.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2024.05.008</ArticleId><ArticleId IdType="pubmed">38821468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampropoulou-Adamidou K., Lelovas P., Karadimas E. V., Liakou C., Triantafillopoulos I. K., Dontas I., et al. (2014). Useful animal models for the research of osteoarthritis. Eur. J. Orthop. Surg. and Traumatology Orthop. Traumatologie 24 (3), 263–271. 10.1007/s00590-013-1205-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-013-1205-2</ArticleId><ArticleId IdType="pubmed">23508348</ArticleId></ArticleIdList></Reference><Reference><Citation>Loga I. S. von, Batchelor V., Driscoll C., Burleigh A., Chia S.-Lu L., Stott B., et al. (2020). Does pain at an earlier stage of chondropathy protect female mice against structural progression after surgically induced osteoarthritis? Arthritis and Rheumatology (Hoboken, N.J.) 72 (12), 2083–2093. 10.1002/art.41421</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41421</ArticleId><ArticleId IdType="pubmed">32602242</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W., St-Jacques B., Rudakou U., Kim Y. N. (2017). Stimulating TRPV1 externalization and synthesis in dorsal root ganglion neurons contributes to PGE2 potentiation of TRPV1 activity and nociceptor sensitization. Eur. J. Pain London, Engl. 21 (4), 575–593. 10.1002/ejp.959</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejp.959</ArticleId><ArticleId IdType="pubmed">27739618</ArticleId></ArticleIdList></Reference><Reference><Citation>Marttila-Ichihara F., Smith D. J., Craig S., Yegutkin G. G., Elima K., Mercier N., et al. (2006). Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo . Arthritis Rheumatism 54 (9), 2852–2862. 10.1002/art.22061</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22061</ArticleId><ArticleId IdType="pubmed">16947396</ArticleId></ArticleIdList></Reference><Reference><Citation>Matyus P., Chai C. L. L. (2016). Metabolism-activated multitargeting (MAMUT): an innovative multitargeting approach to drug design and development. ChemMedChem 11 (12), 1197–1198. 10.1002/cmdc.201500406</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201500406</ArticleId><ArticleId IdType="pubmed">26497424</ArticleId></ArticleIdList></Reference><Reference><Citation>McDougall J. J., Muley M. M., Philpott H. T., Allison R., Eugene K. (2017). Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice. Arthritis Res. and Ther. 19 (1), 106. 10.1186/s13075-017-1313-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1313-1</ArticleId><ArticleId IdType="pmc">PMC5445456</ArticleId><ArticleId IdType="pubmed">28545594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan G., Perilli E., Kuliwaba J. S., Humphries J. M., Parkinson I. H., Fazzalari N. L. (2011). Application of in vivo micro-computed tomography in the temporal characterisation of subchondral bone architecture in a rat model of low-dose monosodium iodoacetate-induced osteoarthritis. Arthritis Res. and Ther. 13 (6), R210. 10.1186/ar3543</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3543</ArticleId><ArticleId IdType="pmc">PMC3334663</ArticleId><ArticleId IdType="pubmed">22185204</ArticleId></ArticleIdList></Reference><Reference><Citation>Moilanen L. J., Hämäläinen M., Nummenmaa E., Ilmarinen P., Vuolteenaho K., Nieminen R. M., et al. (2015). Monosodium iodoacetate-induced inflammation and joint pain are reduced in TRPA1 deficient mice - potential role of TRPA1 in osteoarthritis. Osteoarthr. Cartil. 23 (11), 2017–2026. 10.1016/j.joca.2015.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2015.09.008</ArticleId><ArticleId IdType="pubmed">26521748</ArticleId></ArticleIdList></Reference><Reference><Citation>Neogi T. (2013). The epidemiology and impact of pain in osteoarthritis. Osteoarthr. Cartil. 21 (9), 1145–1153. 10.1016/j.joca.2013.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2013.03.018</ArticleId><ArticleId IdType="pmc">PMC3753584</ArticleId><ArticleId IdType="pubmed">23973124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neogi T., Zhang Y. (2013). Epidemiology of osteoarthritis. Rheumatic Dis. Clin. North America 39 (1), 1–19. 10.1016/j.rdc.2012.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2012.10.004</ArticleId><ArticleId IdType="pmc">PMC3545412</ArticleId><ArticleId IdType="pubmed">23312408</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Brien M., Philpott H. T., McDougall J. J. (2017). Understanding osteoarthritis pain through animal models. Clin. Exp. Rheumatology 35 (Suppl 1), 47–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28967367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogbonna A. C., Clark A. K., Gentry C., Hobbs C., Malcangio M. (2013). Pain-like behaviour and spinal changes in the monosodium iodoacetate model of osteoarthritis in C57Bl/6 mice. Eur. J. Pain London, Engl. 17 (4), 514–526. 10.1002/j.1532-2149.2012.00223.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1532-2149.2012.00223.x</ArticleId><ArticleId IdType="pubmed">23169679</ArticleId></ArticleIdList></Reference><Reference><Citation>Oo W. M., Little C., Duong V., Hunter D. J. (2021). The development of disease-modifying therapies for osteoarthritis (DMOADs): the evidence to date. Drug Des. Dev. Ther. 15, 2921–2945. 10.2147/DDDT.S295224</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S295224</ArticleId><ArticleId IdType="pmc">PMC8273751</ArticleId><ArticleId IdType="pubmed">34262259</ArticleId></ArticleIdList></Reference><Reference><Citation>Orita S., Ishikawa T., Miyagi M., Ochiai N., Inoue G., Eguchi Y., et al. (2011). Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet. Disord. 12 (June), 134. 10.1186/1471-2474-12-134</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-12-134</ArticleId><ArticleId IdType="pmc">PMC3142251</ArticleId><ArticleId IdType="pubmed">21679434</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G., Franklin K. B. J. (2001). Paxinos and franklin’s the mouse brain in stereotaxic coordinates. Second Edition. San Diego: Elsevier.</Citation></Reference><Reference><Citation>Payrits M., Mátyus P., Czompa A., Ludmerczki R., Deme R., Sándor Z., et al. (2016). A novel 3-(4,5-diphenyl-1,3-oxazol-2-Yl)Propanal oxime compound is a potent transient receptor potential ankyrin 1 and vanilloid 1 (TRPA1 and V1) receptor antagonist. Neuroscience 324, 151–162. 10.1016/j.neuroscience.2016.02.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2016.02.049</ArticleId><ArticleId IdType="pubmed">26930003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitcher T., Sousa-Valente J., Malcangio M. (2016). The monoiodoacetate model of osteoarthritis pain in the mouse. J. Vis. Exp. JoVE (111), 53746. 10.3791/53746</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/53746</ArticleId><ArticleId IdType="pmc">PMC4942175</ArticleId><ArticleId IdType="pubmed">27214709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ro J. Y., Zhang Y., Tricou C., Yang D., Joyce T. da S., Zhang R. (2020). Age and sex differences in acute and osteoarthritis-like pain responses in rats. Journals Gerontology. Ser. A, Biol. Sci. Med. Sci. 75 (8), 1465–1472. 10.1093/gerona/glz186</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glz186</ArticleId><ArticleId IdType="pmc">PMC7357590</ArticleId><ArticleId IdType="pubmed">31412104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Merchan E. C. (2023). The current role of disease-modifying osteoarthritis drugs. Archives Bone Jt. Surg. 11 (1), 11–22. 10.22038/ABJS.2021.56530.2807</Citation><ArticleIdList><ArticleId IdType="doi">10.22038/ABJS.2021.56530.2807</ArticleId><ArticleId IdType="pmc">PMC9903308</ArticleId><ArticleId IdType="pubmed">36793668</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar D. R., Burston J. J., Hathway G. J., Woodhams S. G., Pearson R. G., Bennett A. J., et al. (2011). The contribution of spinal glial cells to chronic pain behaviour in the monosodium iodoacetate model of osteoarthritic pain. Mol. Pain 7 (1), 88. 10.1186/1744-8069-7-88</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1744-8069-7-88</ArticleId><ArticleId IdType="pmc">PMC3271989</ArticleId><ArticleId IdType="pubmed">22093915</ArticleId></ArticleIdList></Reference><Reference><Citation>Spahn V., Stein C., Zollner C. (2014). Modulation of transient receptor vanilloid 1 activity by transient receptor potential ankyrin 1. Mol. Pharmacol. 85 (2), 335–344. 10.1124/mol.113.088997</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.113.088997</ArticleId><ArticleId IdType="pubmed">24275229</ArticleId></ArticleIdList></Reference><Reference><Citation>Spil W. E. V., Kubassova O., Boesen M., Bay-Jensen A.-C., Ali M. (2019). Osteoarthritis phenotypes and novel therapeutic targets. Biochem. Pharmacol. 165 (July), 41–48. 10.1016/j.bcp.2019.02.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.02.037</ArticleId><ArticleId IdType="pubmed">30831073</ArticleId></ArticleIdList></Reference><Reference><Citation>Stornetta R. L., Charles P. S., Guyenet P. G. (2002). Vesicular glutamate transporter DNPI/VGLUT2 MRNA is present in C1 and several other groups of brainstem catecholaminergic neurons. J. Comp. Neurology 444 (3), 191–206. 10.1002/cne.10141</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.10141</ArticleId><ArticleId IdType="pubmed">11840474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tábi T., Szöko É., Mérey A., Tóth V., Mátyus P., Gyires K. (2013). Study on SSAO enzyme activity and anti-inflammatory effect of SSAO inhibitors in animal model of inflammation. J. Neural Transm. 120 (6), 963–967. 10.1007/s00702-012-0961-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-012-0961-1</ArticleId><ArticleId IdType="pubmed">23263543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tékus V., Borbély É., Kiss T., Perkecz A., Kemény Á., Horváth J., et al. (2018a). Investigation of lake hévíz mineral water balneotherapy and hévíz mud treatment in murine osteoarthritis and rheumatoid arthritis models. Evidence-Based Complementary Altern. Med. ECAM 2018, 4816905. 10.1155/2018/4816905</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4816905</ArticleId><ArticleId IdType="pmc">PMC6129852</ArticleId><ArticleId IdType="pubmed">30224931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tékus V., Horváth Á. I., Csekő K., Szabadfi K., Kovács-Valasek A., Dányádi B., et al. (2020). Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats. Biomed. and Pharmacother. = Biomedecine and Pharmacother. 134 (December), 111105. 10.1016/j.biopha.2020.111105</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.111105</ArticleId><ArticleId IdType="pubmed">33338750</ArticleId></ArticleIdList></Reference><Reference><Citation>Temp J., Labuz D., Negrete R., Sunkara V., Machelska H. (2020). Pain and knee damage in male and female mice in the medial meniscal transection-induced osteoarthritis. Osteoarthr. Cartil. 28 (4), 475–485. 10.1016/j.joca.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2019.11.003</ArticleId><ArticleId IdType="pubmed">31830592</ArticleId></ArticleIdList></Reference><Reference><Citation>Udo M., Muneta T., Tsuji K., Ozeki N., Nakagawa Y., Ohara T., et al. (2016). Monoiodoacetic acid induces arthritis and synovitis in rats in a dose- and time-dependent manner: proposed model-specific scoring systems. Osteoarthr. Cartil. 24 (7), 1284–1291. 10.1016/j.joca.2016.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2016.02.005</ArticleId><ArticleId IdType="pubmed">26915639</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdrighi N., Blom A. B., van Beuningen H. M., Vitters E. L., Helsen M. M., Walgreen B., et al. (2023). Early pain in females is linked to late pathological features in murine experimental osteoarthritis. PeerJ 11, e15482. 10.7717/peerj.15482</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.15482</ArticleId><ArticleId IdType="pmc">PMC10290834</ArticleId><ArticleId IdType="pubmed">37366428</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsy J. L., Ghandehari J., Dickenson A. H. (2009). Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. Eur. J. Pain London, Engl. 13 (8), 786–793. 10.1016/j.ejpain.2008.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpain.2008.09.008</ArticleId><ArticleId IdType="pubmed">18955000</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. A., Bonnet C. S., Turner E. L., Wilson D., Situ M., McWilliams D. F. (2007a). Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthr. Cartil. 15 (7), 743–751. 10.1016/j.joca.2007.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2007.01.020</ArticleId><ArticleId IdType="pubmed">17376709</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein A. M., Rome B. N., Reichmann W. M., Collins J. E., Burbine S. A., Thornhill T. S., et al. (2013). Estimating the burden of total knee replacement in the United States. J. Bone Jt. Surg. Am. Volume 95 (5), 385–392. 10.2106/JBJS.L.00206</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.L.00206</ArticleId><ArticleId IdType="pmc">PMC3748969</ArticleId><ArticleId IdType="pubmed">23344005</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L. Q., Lin A. S. P., Kundu K., Levenston M. E., Murthy N., Guldberg R. E. (2012a). Quantitative imaging of cartilage and bone morphology, reactive oxygen species, and vascularization in a rodent model of osteoarthritis. Arthritis Rheumatism 64 (6), 1899–1908. 10.1002/art.34370</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34370</ArticleId><ArticleId IdType="pmc">PMC3366030</ArticleId><ArticleId IdType="pubmed">22231023</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing D., Xu Y., Liu Q., Ke Y., Wang B., Li Z., et al. (2016). Osteoarthritis and all-cause mortality in worldwide populations: grading the evidence from a meta-analysis. Sci. Rep. 6 (April), 24393. 10.1038/srep24393</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep24393</ArticleId><ArticleId IdType="pmc">PMC4834546</ArticleId><ArticleId IdType="pubmed">27087682</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Wang P., Xing R., Zhao L., Li X., Zhang Li, et al. (2018). Transient receptor potential ankyrin 1 (TRPA1) mediates lipopolysaccharide (LPS)-Induced inflammatory responses in primary human osteoarthritic fibroblast-like synoviocytes. Inflammation 41 (2), 700–709. 10.1007/s10753-017-0724-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0724-0</ArticleId><ArticleId IdType="pubmed">29318481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>